2,3-dihydroxyquinoxaline has been researched along with 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furuya, T; Hidaka, K; Kawasaki, S; Kubota, H; Murase, K; Ohmori, J; Okada, M; Sakamoto, S; Shimizu-Sasamata, M; Togami, J | 1 |
| Carcache, D; Kalkman, HO; Koller, M; Mattes, H | 1 |
2 other study(ies) available for 2,3-dihydroxyquinoxaline and 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
| Article | Year |
|---|---|
6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Binding Sites; Brain; Imidazoles; Male; Mice; Mice, Inbred DBA; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Seizures; Structure-Activity Relationship | 1994 |
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
Topics: Analgesics; Animals; Anticonvulsants; Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Protein Subunits; Receptors, AMPA | 2010 |